دورية أكاديمية
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
| العنوان: | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma |
|---|---|
| المؤلفون: | Finn, Richard S., Ikeda, Masafumi, Zhu, Andrew X., Sung, Max W., Baron, Ari D., Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E., Saito, Kenichi, Siegel, Abby B., Dubrovsky, Leonid, Mody, Kalgi, Llovet i Bayer, Josep Maria |
| المصدر: | Articles publicats en revistes (Medicina) |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2020 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Immunoglobulines, Tumors, Medicaments, Immunoglobulins, Drugs |
| الوصف: | PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an anti-PD-1 antibody) in unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients with uHCC received lenvatinib (bodyweight $ 60 kg, 12 mg; , 60 kg, 8 mg) orally daily and pembrolizumab 200 mg intravenously on day 1 of a 21- day cycle. The study included a dose-limiting toxicity (DLT) phase and an expansion phase (first-line patients). Primary objectives were safety/tolerability (DLT phase), and objective response rate (ORR) and duration of response (DOR) by modified RECIST (mRECIST) and RECIST version 1.1 (v1.1) per independent imaging review (IIR; expansion phase). RESULTS A total of 104 patients were enrolled. No DLTs were reported (n 5 6) in the DLT phase; 100 patients (expansion phase; included n 5 2 from DLT phase) had received no prior systemic therapy and had Barcelona Clinic Liver Cancer stage B (n 5 29) or C disease (n 5 71). At data cutoff, 37% of patients remained on treatment. Median duration of follow-up was 10.6 months (95% CI, 9.2 to 11.5 months). Confirmed ORRs by IIR were 46.0% (95% CI, 36.0% to 56.3%) per mRECIST and 36.0% (95% CI, 26.6% to 46.2%) per RECIST v1.1. Median DORs by IIR were 8.6 months (95% CI, 6.9 months to not estimable [NE]) per mRECIST and 12.6 months (95% CI, 6.9 months to NE) per RECIST v1.1. Median progression-free survival by IIR was 9.3 months per mRECIST and 8.6 months per RECIST v1.1. Median overall survival was 22 months. Grade $ 3 treatment-related adverse events occurred in 67% (grade 5, 3%) of patients. No new safety signals were identified. CONCLUSION Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 20 p.; application/pdf |
| اللغة: | English |
| تدمد: | 0936-6555 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1200/JCO.20.00808Test; Clinical Oncology, 2020, vol. 38, num. 26, p. 2960-2970; https://doi.org/10.1200/JCO.20.00808Test; http://hdl.handle.net/2445/174833Test; 706130 |
| الإتاحة: | https://doi.org/10.1200/JCO.20.00808Test http://hdl.handle.net/2445/174833Test |
| حقوق: | cc-by-nc-nd (c) Finn et. al., 2020 ; http://creativecommons.org/licenses/by-nc-nd/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7F26CC41 |
| قاعدة البيانات: | BASE |
| تدمد: | 09366555 |
|---|